Farnesoid X receptor modulators: a patent review

Bibliography

• Seol W, Choi HS, Moore DD. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol Endocrinol 1995;9:72-85
   PubMed Web of Science ®Google Scholar
• Forman BM, Goode E, Chen J, Identification of a nuclear receptor that is activated by faresol metabolites. Cell 1995;81:687-93
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Hollister K, Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-53
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 2005;48:5383-403
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Rizzo G, Donini A, Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007;13:298-309
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Cariou B, Lien F, Role of bile acids receptors in metabolic regulation. Physiol Rev 2009;89:147-91
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003;278:101-10
   Google Scholar
• Sinal CJ, Tohkin M, Miyata M, Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731-44
   PubMed Web of Science ®Google Scholar
• Claudel T, Staels B, Kuipers F. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005;25:2020-30
   PubMed Web of Science ®Google Scholar
• Hirokane H, Nakahara M, Tachibana S, Bile acid reduces the secretion of VLDL by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 2004;279:45685-92
   PubMed Web of Science ®Google Scholar
• Claudel T, Sturm E, Kuipers F, The farnesoid X receptor: a novel drug target? Expert Opin Investig Drugs 2004;13:1135-48
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Costantino G. Potential therapeutic applications of farnesoid X receptor (FXR) modulators. Expert Opin Ther Patents 2006;16:333-41
   Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, 6alpha-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45:3569-72
   PubMed Web of Science ®Google Scholar
• Pellicciari R. Steroids as agonists for FXR. WO02072598; 2002
   Google Scholar
• Intercept Pharm. Novel steroid agonist for FXR. WO2005082925; 2005
   Google Scholar
• Available from: www.clinicaltrials.gov (NCT00501592)
   Google Scholar
• Available from: www.clinicaltrials.gov (NCT00570765)
   Google Scholar
• Intercept Pharm. Novel steroid agonist for FXR. EP1568706; 2004
   Google Scholar
• Pellicciari R. Chemical compounds. WO2004007521; 2004
   Google Scholar
• Pellicciari R. Chemical compounds. US20050080064; 2005
   Google Scholar
• Pellicciari R, Sato H, Gioiello A, Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J Med Chem 2007;50:4265-8
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Macchiarulo A, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009;52:7958-61
   PubMed Web of Science ®Google Scholar
• Intercept Pharm. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions. WO2007095174; 2007
   Google Scholar
• Pellicciari R, Gioiello A, Costantino G, Back door modulation of the farnesoid X receptor: design, synthesis and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives. J Med Chem 2006;49:4208-15
   PubMed Web of Science ®Google Scholar
• Intercept Pharm. Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions. WO2008002573; 2008
   Google Scholar
• Iguchi Y, Kihira K, Nishimaki-Mogami T, Structure–activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 2010;75:95-100
   PubMed Web of Science ®Google Scholar
• Maloney PR, Parks DJ, Haffner CD, Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43:2971-4
   PubMed Web of Science ®Google Scholar
• Akwabi-Ameyaw A, Bass JY, Caldwell RD, Conformationally constrained farensoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW4064. Bioorg Med Chem Lett 2008;18:4339-43
   PubMed Web of Science ®Google Scholar
• Akwabi-Ameyaw A, Bass JY, Caldwell RD, FXR agonist activity of conformationally constrained analogs of GW4064. Bioorg Med Chem Lett 2009;19:4733-9
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corp. Farnesoid X Receptor Agonists. WO2009005998; 2009
   Google Scholar
• SmithKline Beecham Corp. Farnesoid X Receptor Agonists. WO2008157270; 2008
   Google Scholar
• Kainuma M, Makishima M, Hashimoto Y, Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist. Bioorg Med Chem 2007;15:2587-600
   PubMedGoogle Scholar
• Eli Lilly and Co. Compounds and methods for modulating FXR. WO2007092751; 2007
   Google Scholar
• Eli Lilly and Co. Compounds and methods for modulating FXR. WO2007140174; 2007
   Google Scholar
• Eli Lilly and Co. Compounds and methods for modulating FXR. WO2007140183; 2007
   Google Scholar
• Eli Lilly and Co. Compounds and methods for modulating FXR. WO2009012125; 2009
   Google Scholar
• Phenex Pharm. Heterocyclic cyclopropyl-substituted FXR binding compounds. WO2009149795; 2009
   Google Scholar
• Bass JY, Caldwell RD, Caravell JA, Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW-4064. Bioorg Med Chem Lett 2009;19:2969-73
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham Corp. Farnesoid X Receptor Agonists. WO2007076260; 2007
   Google Scholar
• Phenex Pharm. Heterocyclic FXR binding compounds. WO2008025539; 2008
   Google Scholar
• Phenex Pharm. Heterocyclic FXR binding compounds. WO2008025540; 2008
   Google Scholar
• Takeda Pharm. Heterocyclic amid compound and use thereof. WO2007052843; 2007
   Google Scholar
• Feng S, Yang M, Zhang Z, Identification of an N-oxide pyridine GW-4064 analog as a potent FXR agonist. Bioorg Med Chem Lett 2009;19:2595-8
   PubMed Web of Science ®Google Scholar
• X-Ceptor Therapeutics, Inc. Azepinoindole and pyridoindole derivatives as pharmaceutical agents. WO03099821; 2003
   Google Scholar
• Bush B, Flatt BT, Gu XH, Azepinoindole derivatives as pharmaceutical agents. US20050054634; 2005
   Google Scholar
• X-Ceptor Therapeutics. Azepine derivatives as pharmaceutical agents. WO2005009387; 2005
   Google Scholar
• Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents. WO2007070796; 2007
   Google Scholar
• Mahaney PE, Harnish DC, Abou-Gharbia MA. Indoleazepines as a new class of nonsteroidal agonists of the farnesoid X receptor: identification of WAY-362450 (FXR-450) as a clinical candidate for the treatment of dyslipidemia. Section 181. Abs. of Papers of the 235th National ACS Meeting, New Orleans. 6 – 10 April 2008
   Google Scholar
• Available from: www.clinicaltrials.gov (NCT00509756)
   Google Scholar
• Available from: www.clinicaltrials.gov (NCT00499629)
   Google Scholar
• Flatt B, Martin R, Wang T-L, Discovery of XL-335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009;52:904-7
   PubMed Web of Science ®Google Scholar
• Wyeth. 1,4,5,6-Tetrahydro-pyrrolo[2,3-d]azepines and –imidazo[4,5-d]azepines as modulators of nuclear receptor activity. US20090137554; 2009
   Google Scholar
• Wyeth. 1,4,5,6,7,8-Hexahydro-pyrrolo[2,3-d]azepines and –imidazo[4,5-d]azepines as modulators of nuclear receptor activity. US20090131409; 2009
   Google Scholar
• Mehlman JF, Crawley ML, Lundquist JT, Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett 2009;19:5289-92
   PubMedGoogle Scholar
• Lundquist JT, Harnish DC, Kim CY, Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem 2010;53:1774-87
   PubMed Web of Science ®Google Scholar
• Deng G, Li W, Shen J, Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation. Bioorg Med Chem Lett 2008;18:5497-502
   PubMedGoogle Scholar
• Exelixis, Inc. Heterocyclic compounds as pharmaceutical agents. WO2006020680; 2006
   Google Scholar
• F. Hoffman-La Roche AG. Benzimidazole derivatives, method for the production thereof, their use as FXR agonists and pharmaceutical preparations containing the same. WO2008000643; 2008
   Google Scholar
• F. Hoffman-La Roche AG. Novel methyl-benzimidazole derivatives. WO2009062874; 2009
   Google Scholar
• F. Hoffman-La Roche AG. Benzimidazole derivatives used as FXR agonists. WO2009027264; 2009
   Google Scholar
• Hoffman-La Roche, Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives. US20090163552; 2009
   Google Scholar
• Merck Sante. Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators. EP2110374A1; 2009
   Google Scholar
• Merck Patent GMBH. Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators. WO2009127321; 2009
   Google Scholar
• Exelixis Inc. LXR and FXR Modulators. WO2008073825; 2008
   Google Scholar
• Wyeth. FXR agonists for reducing LOX-1 expression. US20080300235; 2008
   Google Scholar
• Wyeth. FXR agonists for the treatment of nonalcoholic fatty liver and cholesterol gallstone diseases. US20090163474; 2009
   Google Scholar
• Wyeth. FXR agonists for treating vitamin D associated diseases. US20090215748; 2009
   Google Scholar
• Intercept Pharm. A method of reducing drug-induced adverse side effects in a patient. WO2006044391; 2006
   Google Scholar
• INSERM. Methods, uses and compositions for modulating replication of HCV through the farnesoid X receptor (FXR) activation of inhibition. WO2008017692; 2008
   Google Scholar
• Wyeth. FXR agonists for the treatment of malignancies. US20080299118; 2009
   Google Scholar